472 related articles for article (PubMed ID: 23273719)
1. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Loh JP; Pendyala LK; Kitabata H; Torguson R; Chen F; Kent KM; Satler LF; Suddath WO; Pichard AD; Waksman R
Am J Cardiol; 2013 Mar; 111(6):841-5. PubMed ID: 23273719
[TBL] [Abstract][Full Text] [Related]
2. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
3. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
[TBL] [Abstract][Full Text] [Related]
4. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
6. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.
Wiviott SD; Desai N; Murphy SA; Musumeci G; Ragosta M; Antman EM; Braunwald E
Am J Cardiol; 2011 Oct; 108(7):905-11. PubMed ID: 21816379
[TBL] [Abstract][Full Text] [Related]
9. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
[TBL] [Abstract][Full Text] [Related]
10. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
12. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
Sarafoff N; Martischnig A; Wealer J; Mayer K; Mehilli J; Sibbing D; Kastrati A
J Am Coll Cardiol; 2013 May; 61(20):2060-6. PubMed ID: 23524219
[TBL] [Abstract][Full Text] [Related]
13. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
[TBL] [Abstract][Full Text] [Related]
16. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
Beigel R; Fefer P; Rosenberg N; Novikov I; Elian D; Fink N; Segev A; Guetta V; Hod H; Matetzky S
Am J Cardiol; 2013 Nov; 112(10):1551-6. PubMed ID: 23972349
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
Montalescot G; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; ten Berg JM; Miller DL; Costigan TM; Goedicke J; Silvain J; Angioli P; Legutko J; Niethammer M; Motovska Z; Jakubowski JA; Cayla G; Visconti LO; Vicaut E; Widimsky P;
N Engl J Med; 2013 Sep; 369(11):999-1010. PubMed ID: 23991622
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of prasugrel use in patients undergoing percutaneous coronary intervention and anticoagulated with bivalirudin.
Laynez A; Sardi G; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2013 Feb; 111(4):516-20. PubMed ID: 23219177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]